Literature DB >> 8761313

Major pharmacological distinction of the ACTH receptor from other melanocortin receptors.

H B Schiöth1, V Chhajlani, R Muceniece, V Klusa, J E Wikberg.   

Abstract

The mouse adrenocortical cell line Y1, that expresses ACTH receptors (MC2R), was used to probe the binding of ACTH and MSH peptides by using radio-labelled ACTH (1-39). The Y1 cells were found to bind [125I]-labelled ACTH (1-39) with high affinity (Kd approximately 130 pM). However, none of the melanocortin peptides NDP-MSH, alpha-MSH, beta-MSH or gamma 1-MSH could compete with the binding of the labelled ACTH(1-39). When other MC receptor subtype DNAs (MC1, MC3 and MC4) were transfected into the Y1 cells, characteristic binding of the [125I]NDP-MSH appeared for each of the receptor subtype, but no specific binding was present in non-transfected cells. This is the first report clearly demonstrating that the ACTH receptor binds only ACTH, but not other melanocortin peptides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761313     DOI: 10.1016/0024-3205(96)00370-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  29 in total

1.  ACTH enhancement of T-lymphocyte cytotoxic responses.

Authors:  Eve W Johnson; Thomas K Hughes; Eric M Smith
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

2.  Conformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor.

Authors:  Paolo Grieco; Diego Brancaccio; Ettore Novellino; Victor J Hruby; Alfonso Carotenuto
Journal:  Eur J Med Chem       Date:  2011-05-23       Impact factor: 6.514

Review 3.  The MC4 receptor and control of appetite.

Authors:  R A H Adan; B Tiesjema; J J G Hillebrand; S E la Fleur; M J H Kas; M de Krom
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

4.  Structure-Activity Relationship Studies on a Macrocyclic Agouti-Related Protein (AGRP) Scaffold Reveal Agouti Signaling Protein (ASP) Residue Substitutions Maintain Melanocortin-4 Receptor Antagonist Potency and Result in Inverse Agonist Pharmacology at the Melanocortin-5 Receptor.

Authors:  Mark D Ericson; Katie T Freeman; Sathya M Schnell; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-10-04       Impact factor: 7.446

5.  Adrenocorticotropic hormone enhances the masculinity of an electric communication signal by modulating the waveform and timing of action potentials within individual cells.

Authors:  Michael R Markham; Philip K Stoddard
Journal:  J Neurosci       Date:  2005-09-21       Impact factor: 6.167

Review 6.  Polymorphisms and mutations in the melanocortin-3 receptor and their relation to human obesity.

Authors:  Andrew P Demidowich; Joo Yun Jun; Jack A Yanovski
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

7.  Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling.

Authors:  Min Chen; Charles J Aprahamian; Robert A Kesterson; Carroll M Harmon; Yingkui Yang
Journal:  Biochemistry       Date:  2007-09-18       Impact factor: 3.162

8.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

9.  Comparative Functional Alanine Positional Scanning of the α-Melanocyte Stimulating Hormone and NDP-Melanocyte Stimulating Hormone Demonstrates Differential Structure-Activity Relationships at the Mouse Melanocortin Receptors.

Authors:  Aleksandar Todorovic; Mark D Ericson; Ryan D Palusak; Nicholas B Sorensen; Michael S Wood; Zhimin Xiang; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2016-05-17       Impact factor: 4.418

10.  Discovery of Novel Potent and Selective Agonists at the Melanocortin-3 Receptor.

Authors:  Alfonso Carotenuto; Francesco Merlino; Minying Cai; Diego Brancaccio; Ali Munaim Yousif; Ettore Novellino; Victor J Hruby; Paolo Grieco
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.